627P - Histopathological response to neoadjuvant chemotherapy is predictive for prognosis in locally advanced gastroesophageal cancer

Date 08 October 2016
Event ESMO 2016 Congress
Session Poster Display
Topics Oesophageal Cancer
Presenter Silvia Spoerl
Citation Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371
Authors S. Spoerl1, S. Al-Batran2, M. Feith3, F. Lordick4, P. Thuss-Patience5, C. Pauligk2, B. Haller6, A. Novotny3, S. Lorenzen1
  • 13rd Department Of Internal Medicine, Klinikum Rechts Der Isar, Technische Universität München, 81675 - München/DE
  • 2Uct University Cancer Center, Nordwest-Krankenhaus, Frankfurt am Main/DE
  • 3Department Of Surgery, Klinikum Rechts Der Isar, Technische Universität München, 81675 - München/DE
  • 4University Cancer Center Leipzig, University Clinic Leipzig, 04103 - Leipzig/DE
  • 5Department Of Hematology, Oncology And Tumorimmunology, Charité, Campus Virchow Klinikum, 13353 - Berlin/DE
  • 6Institute For Medical Statistics And Epidemiology, Technische Universität München, 81675 - München/DE



Neoadjuvant chemotherapy (neoCTx) improves the prognosis of patients (pts) with localized esophagogastric adenocarcinoma (EGC). This retrospective analysis evaluates the predictive value of histopathology on neoCTX.


461 pts with locally advanced EGC (T2/T3 and/or N+) who received neoCTx followed by surgery between 2000 and 2013 were analyzed from four institutions: 314 (68.1%) with intestinal, 94 (20.4%) with diffuse and 53 (11.5%) with mixed histological type according to Laurens classification. Taxane-platinum-fluoropyrimidine (5FU) based triplet or platinum-FU based doublet neoCTX was administered preoperatively to 185 (40.1%) and 276 (59.9%) pts, respectively. Pathological response evaluation according to Becker was performed locally.


Median patients' age was 63 years, 79.8% were male. Tumors were localized in the stomach in 32.5% and EG junction in 67.5%. 96.5% had clinical stage T3/T4 and 93.7% were N+. With a median follow up of 39.6 months (mos), median overall survival (OS) was 66.4 mos. For pts with intestinal type, median OS was 77.9 mos compared to 34.6 mos for diffuse (p 


Pathologic complete response is associated with long-term survival in EGC independent of histopathological subtype. Efforts to increase the rate of pCR by more effective neoCTX are warranted.

Clinical trial identification

Legal entity responsible for the study

Technical University Munich


Technical University Munich


F. Lordick: Receipt of grant/research supports: GSK, Fresenius Biotech, Boehringer. Receipt of honoraria or consultation fees: Amgen, Eli Lilly, Garrymed, MSD. Merck-Serono, Roche, Taiko. Travel support: Bayer, MSD, Amgen, Roche. All other authors have declared no conflicts of interest.